Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report), Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and Alkermes (ALKS – Research Report).
Pfizer (PFE)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer today and set a price target of $29.00. The company’s shares closed last Wednesday at $27.18, close to its 52-week low of $25.20.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $31.42 average price target, representing a 19.3% upside. In a report issued on April 22, Wells Fargo also maintained a Hold rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
Sagimet Biosciences, Inc. Class A (SGMT)
In a report released today, Ed Arce from H.C. Wainwright initiated coverage with a Buy rating on Sagimet Biosciences, Inc. Class A and a price target of $32.00. The company’s shares closed last Wednesday at $4.11.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sagimet Biosciences, Inc. Class A with a $35.33 average price target.
Alkermes (ALKS)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes, with a price target of $35.00. The company’s shares closed last Wednesday at $24.01.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $35.00 average price target, a 46.8% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $29.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PFE:
- PFE Earnings: Pfizer Rises After Smashing Q1 Estimates
- Options Volatility and Implied Earnings Moves Today, May 01, 2024
- Pfizer developing online platform to sell drugs directly to consumer, FT says
- Notable companies reporting before tomorrow’s open
- Longboard initiated with an Outperform at Baird on ‘best-in-class potential
